Alignment healthcare president sells $199,509 in stock

Published 29/03/2025, 01:32
Alignment healthcare president sells $199,509 in stock

Dawn Christine Maroney, President of Alignment Healthcare, Inc. (NASDAQ:ALHC), recently sold a portion of her holdings in the company. According to a recent SEC filing, Maroney sold 11,152 shares of the company’s common stock on March 27, 2025. The shares were sold at a weighted-average price of $17.89, with individual transaction prices ranging from $17.50 to $18.05. The stock, which has delivered an impressive 269% return over the past year, currently trades near its 52-week high of $18.44. This sale was primarily to cover tax withholding obligations associated with the vesting of restricted stock units and does not represent a discretionary trade. According to InvestingPro data, the company currently has a market capitalization of $3.5 billion, though analysts do not anticipate profitability this year. Following the transaction, Maroney retains ownership of 2,362,899 shares in the company.

In other recent news, Alignment Healthcare has reported strong financial results for the fourth quarter of 2024, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of -0.16, beating the forecast of -0.18, and reported revenue of $701.2 million, exceeding the projected $674.97 million. This performance marks a significant milestone as Alignment Healthcare reached its first year of adjusted EBITDA profitability. The company’s total revenue for the year was $2.7 billion, a 48% increase compared to the previous year.

Additionally, Alignment Healthcare’s membership grew by 59% in 2024, with notable expansion outside of California. Looking forward, the company has issued revenue guidance for 2025, projecting figures between $3.72 billion and $3.78 billion, and expects adjusted gross profit to range from $415 million to $445 million. Analyst firms have shown confidence in the company, with Piper Sandler raising its price target to $21 and maintaining an Overweight rating, while Raymond (NSE:RYMD) James increased its price target to $19 and reiterated a Strong Buy rating. These developments reflect a positive outlook for Alignment Healthcare’s future growth and profitability.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.